| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| [2] |
Wen WM, PhD AAAM. Novel agents on the horizon for cancer therapy [J]. Ca Cancer J Clin, 2009, 59(2): 111-137.
|
| [3] |
Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins [J]. Am J Physiol Gastrointest Liver Physiol, 2000, 279(2): G250-G254.
|
| [4] |
Tsukita S, Furuse M. Pores in the wall: claudins constitute tight junction strands containing aqueous pores [J]. J Cell Biol, 2000, 149(1): 13-16.
|
| [5] |
Hayashi D, Tamura A, Tanaka H, et al. Deficiency of claudin-18 causes paracellular h＋ leakage, up-regulation of interleukin-1β, and atrophic gastritis in mice [J]. Gastroenterology, 2012, 142(2): 292-304.
|
| [6] |
Lameris AL, Huybers S, Kaukinen K, et al. Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease [J]. Scand J Gastroentero, 2013, 48(1): 58-69.
|
| [7] |
Pope JL, Bhat AA, Sharma A, et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling [J]. Gut, 2014, 63(4): 622-634.
|
| [8] |
Huang GW, Ding X, Chen SL, et al. Expression of claudin 10 protein in hepatocellular carcinoma: impact on survival [J]. J Cancer Res Clin, 2011, 137(8): 1213-1218.
|
| [9] |
Matsuda Y, Semba S, Ueda J, et al. Gastric and intestinal claudin expression at the invasive front of gastric carcinoma [J]. Cancer Sci, 2007, 98(7): 1014-1019.
|
| [10] |
Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer [J]. J Hematol Oncol, 2017, 10(1): 105.
|
| [11] |
Shinozaki A, Shibahara J, Noda N, et al. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma [J]. Virchows Arch, 2011, 459(1): 73-80.
|
| [12] |
Micke P, Mattsson JSM, Edlund K, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer [J]. Int J Cancer, 2014, 135(9): 2206-2214.
|
| [13] |
Woll S, Schlitter AM, Dhaene K, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms [J]. Int J Cancer, 2014, 134(3): 731-739.
|
| [14] |
Matsuda M, Sentani K, Noguchi T, et al. Immunohistochemical analysis of colorectal cancer with gastric phenotype: Claudin-18 is associated with poor prognosis [J]. Pathol Int, 2010, 60(10): 673-680.
|
| [15] |
Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development [J]. Clin Cancer Res, 2008, 14(23): 7624-7634.
|
| [16] |
Yao F, Kausalya JP, Sia YY, et al. Recurrent fusion genes in gastric cancer: Claudin18-ARH-GAP26 induces loss of epithelial integrity [J]. Cell Rep, 2015, 12(2): 272-285.
|
| [17] |
Jun KH, Kim JH, Jung JH, et al. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer [J]. Int J Surg, 2014, 12(2): 156-162.
|
| [18] |
Oshima T, Shan J, Okugawa T, et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front [J]. PloS One, 2013, 8(9): e74757.
|
| [19] |
王行富，张声，郑珂, 等. Claudin18表达在胃癌进展中的意义 [J]. 中国肿瘤临床, 2011, 38(11): 642-646.
|
| [20] |
杨士贤，吴铁镛，刘晓刚. 胃腺癌组织中紧密连接蛋白7和紧密连接蛋白18及E钙黏素的表达及其意义 [J]. 中国全科医学, 2013, 16(3): 267-270.
|
| [21] |
Sentani K, Oue N, Tashiro T, et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma [J]. Am J Surg Pathol, 2008, 32(8): 1182-1189.
|
| [22] |
宋洁，郭瑞芳，苏日拉, 等. TFF2、Claudin18、MUC5AC蛋白在胃黏膜病变过程中的表达变化及其临床意义 [J]. 胃肠病学, 2015, 20(7): 394-397.
|
| [23] |
Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index [J]. Histopathology, 2006, 48(6): 674-682.
|
| [24] |
Taylor JM, Macklem MM, Parsons JT. Cytoskeletal changes induced by GRAF, the GTPase regulator associated with focal adhesion kinase, are mediated by Rho [J]. J Cell Sci, 1999, 112(Pt2): 231-242.
|
| [25] |
Zhang SJ, Feng JF, Wang L, et al. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells [J]. Dig Dis Sci, 2014, 59(8): 1754-1763.
|
| [26] |
Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks [J]. J Mol Biol, 2013, 425(19): 3582-3600.
|
| [27] |
Li K, Li J. Current molecular targeted therapy in advanced gastric cancer: a comprehensive review of therapeutic mechanism, clinical trials, and practical application [J]. Gastroenterol Res Pract, 2016, 2016: 4105615.
|
| [28] |
吕元皓，季鸣，陈晓光. 胃癌免疫治疗研究进展 [J]. 中国生化药物杂志, 2016, 36(11): 197-199.
|
| [29] |
Al-Batran S, Schuler MH, Zvirbule Z, et al. FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-Claudin18.2 antibody, as first-line therapy in patients with advanced Claudin18.2＋ gastric and gastroesophageal junction (GEJ) adenocarcinoma [J]. J Clin Oncol, 2016, 34(18suppl): A4001.
|
| [30] |
Matsusaka K, Ushiku T, Urabe M, et al. Coupling CDH17 and Claudin18 markers for comprehensive membrane-targeted detection of human gastric cancer [J]. Oncotarget, 2016, 7(39): 64168-64181.
|